Helus Pharma Exec to Discuss Neuroplasticity Drugs at H.C. Wainwright Conference — Cybin Inc.

Event summary

Helus Pharma's Chief Medical Officer Amir Inamdar to participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Conference on June 15-16, 2026.
Session available on demand starting June 15 at 7:00 a.m. EDT.
Helus Pharma developing HLP003 (Phase 3) for major depressive disorder and HLP004 (Phase 2) for generalized anxiety disorder.
HLP003 has received Breakthrough Therapy Designation from the FDA.

The big picture

Helus Pharma's participation in the H.C. Wainwright conference highlights the growing investor interest in novel serotonergic agonists for mental health conditions. The company's focus on neuroplasticity aligns with broader industry trends toward mechanism-based treatments for depression and anxiety. With HLP003's Breakthrough Therapy Designation, Helus Pharma is positioning itself as a potential disruptor in the mental health treatment market, though it faces significant competition from established players and other clinical-stage biotech companies.

What we're watching

Clinical Progress: Whether Helus Pharma can maintain its lead in serotonergic agonist development through successful Phase 3 trials for HLP003.
Regulatory Pathway: How the FDA's Breakthrough Therapy Designation for HLP003 will impact its approval timeline and commercialization strategy.
Market Positioning: The pace at which Helus Pharma can differentiate itself in the competitive mental health treatment landscape.